BlackRock Discloses Significant Stake in Cullinan Oncology
Ticker: CGEM · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1789972
| Field | Detail |
|---|---|
| Company | Cullinan Oncology, Inc. (CGEM) |
| Form Type | SC 13G |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, biotech
TL;DR
**BlackRock's holding in Cullinan Oncology is a bullish signal for the stock.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds a significant stake in Cullinan Oncology, Inc. This filing indicates BlackRock's continued confidence in Cullinan Oncology, a biotechnology company, by maintaining a substantial ownership position. For investors, this means a large institutional player sees value in Cullinan Oncology, which can be a positive signal, potentially influencing stock stability and future investor interest.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a notable stake in Cullinan Oncology, which can signal confidence and potentially attract other investors.
Risk Assessment
Risk Level: low — This filing indicates a stable institutional holding, which generally reduces volatility and risk for the stock.
Analyst Insight
A smart investor would view BlackRock's continued holding as a positive sign of institutional confidence in Cullinan Oncology and might consider further research into the company's fundamentals.
Key Players & Entities
- BlackRock Inc. (company) — the investment firm filing the SC 13G
- Cullinan Oncology, Inc. (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G
Forward-Looking Statements
- BlackRock will maintain its significant stake in Cullinan Oncology for the foreseeable future. (BlackRock Inc.) — medium confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically filed under Rule 13d-1(b) as indicated by the 'X' in the appropriate box.
Who is the subject company of this filing?
The subject company is Cullinan Oncology, Inc., with a Central Index Key (CIK) of 0001789972.
Who is the entity that filed this SC 13G?
The entity that filed this SC 13G is BlackRock Inc., with a Central Index Key (CIK) of 0001364742.
What is the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 31, 2023.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Cullinan Oncology, Inc. is 230031106.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 regarding Cullinan Oncology, Inc. (CGEM).